Defendant

Wockhardt Limited

3 cases as defendant.

Cases
3
Active
0
3 closed
Filed
2015
Top venue
D. New Jersey
2 cases

Company profile

Company overview. Wockhardt Limited (NSE: WOCKPHARMA; BSE: 532300) is an Indian pharmaceutical and biotechnology company founded in 1967 by Dr. Habil Khorakiwala, with registered operations dating to 1973 and incorporation as Wockhardt Ltd. in 1999. It is headquartered at Wockhardt Towers, Bandra-Kurla Complex, Mumbai, and is publicly listed — not a subsidiary. Size estimates vary by source: recent filings and market data put revenue at roughly ₹33–35 billion (about US$350–400 million) for FY2025–26, with employee counts cited between roughly 2,500 and 4,100 depending on the reporting date. Market capitalization has been reported in the hundreds of billions of rupees on Indian exchanges.

Products / operations. Wockhardt operates as a genuine, large-scale manufacturer. It makes branded and generic finished formulations, active pharmaceutical ingredients (APIs), biopharmaceuticals, nutrition products and vaccines, with manufacturing in India, the UK, Ireland, France and the US (including Morton Grove Pharmaceuticals), and subsidiaries including Wockhardt Bio AG in Switzerland. Therapeutic strengths include anti-infectives, pain management, diabetes, nephrology, neuropsychiatry and dermatology. Its biotech line includes recombinant human insulin (Wosulin), insulin glargine (Glaritus) and insulin delivery devices. Its discovery program focuses on novel antibiotics against antimicrobial resistance, including zidebactam/cefepime (Zaynich), nafithromycin (Miqnaf) and ertapenem/zidebactam (Odrate). It also runs Wockhardt Hospitals and offers contract manufacturing/custom research.

Patent-litigation posture. The tracked data show Wockhardt as a defendant in two 2015 cases and never as a plaintiff — the signature of an operating company defending infringement claims rather than an NPE. Both tracked suits were filed in the US District Court for the District of New Jersey, not a plaintiff-friendly venue such as the Eastern District of Texas. There is no evidence in the case data of Wockhardt asserting patents offensively.

Notable cases. Both tracked matters are Jazz Pharmaceuticals, Inc. et al. v. Wockhardt Bio AG et al. (D.N.J., filed July 17, 2015), Hatch-Waxman ANDA litigation over generic sodium oxybate (Xyrem). Jazz's filings state that it sued after Wockhardt Bio AG submitted an ANDA and a Paragraph IV certification. The parties settled in April 2016; Wockhardt also filed IPR petitions, which were terminated after settlement. Jazz disclosed that the settlement licensed Wockhardt to sell generic Xyrem on or after December 31, 2025, subject to confidential terms.

Jazz Pharmaceuticals, Inc. et al. v. Wockhardt Bio AG et al.

settled
Docket:
2:15-cv-05619
Filed:
2015-07-17
Patents:8457988

Jazz Pharmaceuticals and Jazz Pharmaceuticals Ireland sued Wockhardt entities in D.N.J. over ANDA No. 207526. Wockhardt filed counterclaims for declaratory judgment of invalidity/non-infringement of the '988 patent and others, and later settled before the Federal Circuit decision.

Jazz Pharmaceuticals, Inc. et al. v. Wockhardt Bio AG et al.

dismissed
Docket:
2:15-cv-05619
Filed:
2015-07-17
Patents:8772306

Resolved by a stipulation/consent judgment of dismissal. Wockhardt admitted the ANDA filing was a technical act of infringement of the asserted patents, expressly including 8,772,306, and was enjoined except as permitted by the April 18, 2016 license agreement.

Eli Lilly and Company v. Wockhardt Limited et al.

judgment
Docket:
1:08-cv-01547
Terminated:
2011-03-21
Patents:5023269

Lilly sued Wockhardt and related entities for infringement of claims 10 and 11 of US 5,023,269. The court entered final judgment for Lilly on March 21, 2011, finding infringement and upholding validity and enforceability. The lead case number was 1:08-cv-1547-TWP-TAB.